天宇股份：奥美沙坦酯氢氯噻嗪片获得美国FDA上市批准

Core Viewpoint - Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Node Pharmaceuticals, has received approval from the U.S. Food and Drug Administration (FDA) for the abbreviated new drug application (ANDA) of Olmesartan Medoxomil and Hydrochlorothiazide tablets, which are primarily used for the treatment of hypertension [1] Company Summary - Tianyu Co., Ltd. is expanding its product portfolio in the pharmaceutical sector with the FDA approval of a new generic drug [1] - The approved drug is aimed at addressing the hypertension market, which is significant given the prevalence of high blood pressure in the population [1] Industry Summary - The approval of generic drugs like Olmesartan Medoxomil and Hydrochlorothiazide is indicative of the ongoing growth and competitiveness in the pharmaceutical industry, particularly in the hypertension treatment segment [1] - The FDA's approval process for generic drugs is crucial for increasing access to affordable medications in the healthcare market [1]